2020年9月、エスケタミンは米国FDAによってうつ病治療薬として承認された最初の幻覚剤となったが、条件付きであった。

幻覚剤（サイケデリックドラッグ）は、古代から世界中の様々な文化において、神秘的な目的や連想のために使用されてきました。考古学者たちは、幻覚剤となる植物が1万年前から人類の儀式において広く利用されてきたことを示唆する化石証拠を記録しています。1990年代には、神経画像診断技術の進歩により、脳マッピング技術によって、研究者たちは動物と人間における幻覚剤の作用機序を解明できるようになりました。

完全なレポートは、 https://www.databridgemarketresearch.com/reports/global-psychedelic-drugs-marketでご覧いただけます。 

データブリッジ市場調査は、市場は2022年から2029年の予測期間に13.3%のCAGRで成長し、2021年の23億8,672万米ドルから2029年には64億195万米ドルに達すると分析しています。大うつ病、心的外傷後ストレス障害、パニック障害、治療抵抗性うつ病、麻薬中毒は、これらの薬が治療する症状のほんの一部です。リゼルグ酸誘導体（LSD）は、ブロッター、ドット、シュガー、アシッド、トリップ、ウィンドウペインとも呼ばれ、ケタミンはビタミンK、バンプ、グリーン、K /スペシャルK、パープル、スーパーアシッドとも呼ばれ、PCPはエンジェル / エンジェルダスト、ボート / ラブボート、ピース、キラーウィード、スーパーグラス、オゾンとも呼ばれ、サイケデリックドラッグの他の名前の一部です。

うつ病治療における幻覚剤の受け入れ拡大が市場の成長率を押し上げると予想される

特に若者の間でうつ病の罹患率が急上昇していることは、市場の成長余地を拡大させるでしょう。サイケデリック薬は、人間の精神的な治癒や治療に深く関わっており、心を癒す力を持つことから、過去10年間で大きな人気を博しました。公的機関と民間企業による医療インフラ整備への支出増加も、市場の成長率を押し上げるでしょう。サイケデリック薬の継続的な研究開発により、米国ではサイケデリック薬の受容度が高まっています。

レポートの範囲と市場セグメンテーション

セグメント分析:

世界の幻覚剤市場は、出所、種類、薬物、用途、投与経路、最終使用者、流通チャネルに基づいて 7 つの主要なセグメントに分類されています。

• サイケデリック薬物市場は、種類別にエンパトゲン、解離性薬物、その他に分類されます。2022年には、エンパトゲンが感情的な共感、一体感、関連性といった体験をもたらし、脱力発作、ナルコレプシー、および関連疾患の治療に使用されることから、世界のサイケデリック薬物市場において74.14%のシェアを占めると予想されています。
• 幻覚剤市場は、原料に基づいて合成と天然に分類されます。2022年には、合成セグメントが世界の幻覚剤市場を99.98%のシェアで支配すると予想されています。これは、ほとんどの製品が人工化学物質から作られており、シロシビンなどの天然成分から作られた製品はごくわずかであるためです。
• 薬物の種類別に見ると、幻覚剤市場はγ-ヒドロキシ酪酸、ケタミン、シロシビン、その他に分類されます。2022年には、γ-ヒドロキシ酪酸セグメントが世界の幻覚剤市場を席巻し、64.09%の市場シェアを獲得すると予想されています。これは、γ-ヒドロキシ酪酸を有効成分とするジャズ・ファーマシューティカル社のキシレムが、市場で最も古い幻覚剤の一つであり、大きなシェアを占め、この薬物クラスに属しているためです。
• On the basis of application, the psychedelic drugs market is segmented into narcolepsy, treatment resistant depression major depressive disorder, opiate addiction, post-traumatic stress disorder and others. In 2022, the narcolepsy segment is expected to dominate the global psychedelic drugs market with 59.50% market share as large number of population suffers from narcolepsy.
• On the basis of route of administration, the psychedelic drugs market is segmented into oral, inhalation and injectable. In 2022, the oral segment is expected to dominate the global psychedelic drugs market with 75.95% market share. It offers several advantages including safety, easier patient compliance and pain/inconvenience avoidance.

The oral segment is expected to dominate the global psychedelic drugs market

The oral route of administration is expected to dominate the market in 2022. This is because this route of administration is the most convenient one and is largely known and accepted. Moreover, rising number of pharmaceutical drugs in the market on daily basis will further push the growth rate of this segment.

• On the basis of end user, the psychedelic drugs market is segmented into hospitals, specialty clinics, homecare and others. In 2022, the hospitals segment is expected to dominate the global psychedelic drugs market with 57.69% market share due to the high patient load and most of the drugs are given under doctor’s supervision. Due to this reason, hospitals segment dominates the psychedelic drugs market.

• On the basis of distribution channel, the psychedelic drugs market is segmented into hospitals pharmacy, retail pharmacy and online pharmacy. In 2022, the hospitals pharmacy segment is expected to dominate the global psychedelic drugs market with 67.78% market share as more number of patients are treated in hospitals and the demand for medicines in hospital pharmacy increases. 

Hospital pharmacy is expected to dominate the distribution channel segment of the global psychedelic drugs market

Rising number of hospitals, healthcare facilities and pharmacies is a direct market growth determinant for this segment. Also, increasing rate of hospitalization especially in the developing and backward economies will further widen the scope of growth for the market.

Major Players

Data Bridge Market Research recognizes the following companies as the major invisible orthodontics market players in advanced wound care market are Pfizer Inc. (U.S.) and Verrian (Germany).

Market Development

• In 2020, Mind Medicine Inc. is undergoing clinical trials for psychedelic drugs in Thailand. The psychedelic drug called ibogaine, is currently in Phase II Clinical Trials and also the procedure is being governed by the Food and Drug Administration.
• A new project for the clinical development of psychedelic substances including psilocybin, LSD, and MDMA for the treatment of various mental diseases was announced by Cure Pharmaceutical Holding Corp. in March 2021.
• Successful results from the Kernel Flow Piloting of the Feasibility Study Measuring Ketamine's Effects on the Brain were announced by Cybin and Kernel on May 9, 2022.
• The Chopra Foundation and Cybin Inc. have announced a partnership to spread knowledge and awareness of the potential benefits of using psychedelics to support mental and physical health and well-being on February 15, 2022.

Regional Analysis

Geographically, the countries covered in the psychedelic drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in psychedelic drugs market during the forecast period 2022 - 2029

North America was anticipated to have a sizable share and was anticipated to continue doing so during the forecast period. The majority of the population in the United States experiences mental health illnesses, making it the most impacted country in the world. As a result, the demand is much larger in the North American region than it is in other nations due to the region's growing patient population. 

Asia-Pacific is estimated to be the fastest growing region in psychedelic drugs market the forecast period 2022 - 2029

The region with the highest growth rate during the predicted period will be Asia-Pacific. Growing public awareness of mental health conditions like depression, obsessive compulsive disorder, and stress is anticipated to spur the market expansion for psychedelic drugs. It is also predicted that factors such as rising economic stress, unstable family arrangements, and other factors will hasten market expansion.

COVID-19 Impact Analysis

People's freedom of movement has been curtailed by the COVID-19 epidemic, which has also kept them confined to their houses, caused great trauma and stress in the form of sadness and loneliness, and has had an impact on people's mental health. People are consequently dealing with physical issues, including sadness and anxiety, in many nations. The market for psychedelic pharmaceuticals, which has significant promise for treating mental diseases, is projected to experience increased demand and, as a result, draw significant investments in the near future.

For more detailed information about the psychedelic drugs market report, click here – https://www.databridgemarketresearch.com/reports/global-psychedelic-drugs-market